Actinium Pharmaceuticals will showcase ATNM-400's preclinical efficacy in therapy-resistant breast cancer at the upcoming SABCS 2026, emphasizing its potential across various cancers.

Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.

Actinium Pharmaceuticals (ATNM) announced an ASH 2026 abstract evaluating long-term safety of Actimab-A plus CLAG-M chemotherapy in relapsed or refractory acute myeloid leukemia.The Phase 1 follow-up examines blood count recovery and potential delayed kidney and liver toxicities among patients who survived at least three months after treatment. Previously presented ASH 2022 data reported estimated one-year and two-year overall survival of 59% and 32% in patients previously treated with venetoclax, and 51% and 19% in patients with TP53-mutated disease. Actinium said the findings support further evaluation of Actimab-A as a potential treatment backbone across mutations in CD33-positive AML. The poster is scheduled for December 13, 2026.

Actinium Pharmaceuticals (ATNM) granted a newly hired non-executive employee an option to purchase 3,000 common shares on October 26, 2026.The option has a $1.40 exercise price, equal to the stock's closing price that day, and a ten-year term. Of the underlying shares, 28% vest on the grant's first anniversary; the remainder vest in monthly installments of 2% over the following 36 months. Vesting requires continued service through each applicable date. The employment inducement award was granted outside the Amended and Restated 2019 Stock Plan under the 2026 Employment Inducement Award Plan.

Actinium Pharmaceuticals (ATNM) will feature its first-in-human Phase 1 study of ATNM-400 at ESMO 2026, held October 23–27 in Madrid. The investigational radiotherapy targets HER3 rather than PSMA in metastatic castration-resistant prostate cancer, disease that has spread and resists testosterone-lowering treatment.The study combines Zirconium-89-labeled imaging with Actinium-225 treatment to assess safety and establish a recommended Phase 2 dose. Patients with positive imaging proceed to treatment every six weeks for up to four cycles. Enrollment includes patients with and without prior PSMA-directed therapy. Initial imaging results showed tumor uptake and retention through Day 7; the company described initial tolerability as encouraging. The ESMO presentation is a trial-in-progress ePoster, with additional study assessments covering radiation exposure, drug behavior in the body and antitumor activity.

Actinium Pharmaceuticals has unveiled promising preclinical results for ATNM-400 at EANM 2026, highlighting its effectiveness across various cancers.

Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in differentiated targeted radiotherapies with the potential to transform cancer treatment, today announced en...

Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.

Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.

Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in differentiated targeted radiotherapies with the potential to transform cancer treatment, today announced ne...

Reported Tuesday, Oct 20 - 8:07am EDT (TheFly subscription required to read more.)

Actinium Pharmaceuticals showcased promising results for ATNM-400, a novel HER3-targeted radiotherapy, showing strong initial safety and efficacy data in prostate cancer treatment at EANM 2026.

Actinium Pharmaceuticals presented groundbreaking data for ATNM-400, targeting prostate and lung cancers at EANM 2026, showcasing its potential across various tumors.

Actinium Pharmaceuticals (ATNM) will present early clinical and preclinical ATNM-400 data at the European Association of Nuclear Medicine congress on October 19, 2026.The clinical presentation covers an ongoing first-in-human Phase 1 dose-escalation study in metastatic castration-resistant prostate cancer. It will describe evaluation of a Zirconium-89-labeled imaging counterpart, including safety, distribution in the body, radiation dosing and PET imaging, to inform development and dosing of Actinium-225-labeled ATNM-400.The preclinical presentation covers KRAS- and ALK-driven non-small cell lung cancer models, evaluating ATNM-400 alone and with KRAS or ALK inhibitors. Actinium is developing the investigational HER3-targeted radiotherapy for use alone and in combinations across multiple solid tumors. Both presentations are scheduled for 4:45–6:15 p.m. CEST in Vienna.

Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in differentiated targeted radiotherapies with the potential to transform cancer treatment, today reminded inv...

Click to view the official SEC document.

Click to view the official SEC document.

At EANM 2026, Actinium Pharmaceuticals unveils groundbreaking findings on ATNM-400's antitumor potential across various cancer models, indicating significant advancements in treatment.

Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in differentiated targeted radiotherapies with the potential to transform cancer treatment, today announced th...

Actinium Pharmaceuticals (ATNM) granted inducement equity awards to its newly appointed chief financial officer and senior vice president of business development.CFO Matt David received options for 250,000 shares at $0.97 on October 14, 2026, plus 250,000 restricted stock units (RSUs) and up to 75,000 milestone-based RSUs. Business development executive Sean Maenpaa received options for 40,000 shares at $1.06 on October 12, 2026, plus 20,000 RSUs and 50,000 RSUs subject to corporate milestones. Both options have ten-year terms, with exercise prices equal to the respective grant-date closing share prices. The awards were granted outside the 2019 Stock Plan under the 2026 Employment Inducement Award Plan.